Agilent Technologies
A
$131.14
+0.41%
Agilent Technologies Inc. is a leading life sciences and diagnostics company that provides measurement technologies to customers in biopharmaceutical, chemical, clinical, and applied markets. Originally spun out of Hewlett-Packard in 1999, Agilent has established itself as a diversified player with a sticky customer base, generating over half its sales from biopharma and advanced materials. The current investor narrative centers on the company's recent earnings beat and raised full-year profit forecast, which has reignited optimism around its growth trajectory and margin expansion, while the acquisition of Biocare Medical signals a strategic push into high-margin pathology innovation.…
A
Agilent Technologies
$131.14
Related headlines
Investment Opinion: Should I buy A Today?
Rating: Hold. Agilent is a quality company with strong margins and a healthy balance sheet, but its premium valuation and recent price weakness warrant caution. The analyst consensus is Overweight/Buy, with an estimated average target of ~$175 (based on forward P/E of 19.8x on consensus EPS of $8.82), implying 34% upside. However, the stock has underperformed the S&P 500 year-to-date (-5.3% vs +9.2%), and the 1-month relative strength is negative.
Supporting evidence: (1) Revenue growth of 6.96% YoY in Q1 FY2026, accelerating from 5.0% in Q4 FY2025. (2) Net margin of 17.0%, above the industry average of ~15%. (3) Free cash flow of $993M TTM, supporting dividends and buybacks. (4) Forward P/E of 19.8x, which is reasonable if earnings grow as expected. However, the PEG ratio of 9.4x is high, and the stock trades at a 45% premium to the industry median P/E of 22x.
Risks & Conditions: The Hold rating would upgrade to Buy if the stock pulls back to $115 (near the 52-week low) or if revenue growth accelerates above 10%. It would downgrade to Sell if growth decelerates below 5% or margins contract. The stock appears fairly valued relative to its own history (P/E below 5-year average) but overvalued relative to peers. Investors should wait for a better entry point or confirmation of sustained growth.
Sign up to view all
A 12-Month Price Forecast
Agilent's fundamentals are solid with improving margins and a strong balance sheet, but the valuation is stretched relative to peers and the PEG ratio is high. The stock's recent underperformance and mixed technical signals suggest near-term uncertainty. The base case of steady growth and range-bound trading is most likely (50% probability). A bullish stance would require confirmation of sustained growth acceleration and margin expansion, while a bearish stance would be triggered by a growth deceleration or macro shock. The neutral stance reflects balanced risk/reward at current levels.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Agilent Technologies's 12-month outlook, with a consensus price target around $170.48 and implied upside of +30.0% versus the current price.
Average Target
$170.48
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$105 - $170
Analyst target range
Agilent is covered by 7 analysts, with a consensus leaning bullish. The average EPS estimate for the current fiscal year is $8.82, with a range of $8.72 to $8.92, and average revenue estimate of $9.37 billion. While explicit price targets are not provided, the consensus recommendation based on recent ratings is Overweight/Buy, with firms like Morgan Stanley, Barclays, and TD Cowen maintaining positive stances. The implied upside from the current price of $130.69 to the average target (if we assume a forward P/E of 19.8x on consensus EPS of $8.82 gives a target of ~$175) would be approximately +34%, though this is an estimate. The recent upgrades from Evercore ISI (Outperform from In Line) and Barclays (Overweight from Equal Weight) indicate growing confidence. The range of analyst estimates for EPS is tight (8.72–8.92), suggesting high conviction in near-term earnings. The high end of the range implies strong operational execution and margin expansion, while the low end may factor in macro headwinds or competitive pressures. The absence of explicit price targets in the data limits precision, but the positive rating momentum and earnings beat suggest a favorable outlook.
Bulls vs Bears: A Investment Factors
Agilent presents a mixed picture: strong operational execution with a Q1 beat, expanding margins, and a healthy balance sheet support the bull case, while a premium valuation (PEG 9.4x, P/E 45% above industry) and recent price weakness favor the bears. The bull case currently has stronger evidence given the earnings momentum and raised guidance, but the key tension is whether the company can sustain its growth trajectory to justify the premium. If revenue growth accelerates above 7% and margins continue to expand, the stock could re-rate higher; if growth disappoints, the premium could compress significantly.
Bullish
- Strong Q1 Earnings Beat and Raised Guidance: Agilent reported Q1 FY2026 revenue of $1.798B, up 6.96% YoY, and raised its full-year profit forecast, signaling robust operational momentum. This beat reignited optimism and drove a 17% surge on May 28, 2026.
- Expanding Profit Margins: Net margin improved to 17.0% in Q1 FY2026 from 12.9% in Q2 FY2025, and gross margin rose to 52.6% from 51.9% a year ago. Operating margin of 19.6% is consistent with industry averages, reflecting operational efficiency.
- Healthy Balance Sheet and Cash Flow: Debt-to-equity is a conservative 0.50, current ratio is 1.96, and trailing twelve-month free cash flow is $993M, yielding 2.4% FCF yield. This provides financial flexibility for acquisitions and shareholder returns.
- Strategic Acquisition in High-Margin Pathology: The acquisition of Biocare Medical in March 2026 accelerates Agilent's push into pathology innovation, a high-margin growth area. This aligns with the company's strategy to expand in diagnostics and applied markets.
Bearish
- High PEG Ratio Indicates Expensive Growth: The PEG ratio of 9.4x suggests the stock is expensive relative to its near-term earnings growth rate. This implies the market is pricing in above-average growth that may not materialize if macro headwinds persist.
- Premium Valuation vs. Industry Peers: Agilent's trailing P/E of 31.9x is a 45% premium to the Medical - Diagnostics & Research industry median of ~22x. While partially justified by superior margins, the premium leaves little room for error.
- Recent Price Weakness and Momentum Divergence: Despite the Q1 beat, the stock is down 3.2% in the last month and 5.3% year-to-date. The 1-month relative strength vs. S&P 500 is -1.98%, indicating underperformance and potential consolidation.
- Macro and Geopolitical Headwinds: Sticky inflation and a hawkish Fed could compress growth stock multiples. Additionally, US-Iran tensions and trade uncertainties may impact Agilent's global operations, particularly in China, which is a key market.
A Technical Analysis
Agilent's stock is in a recovery phase after a significant downturn, with the 1-year price change of +8.3% masking a volatile journey. The current price of $130.69 sits at 33% of its 52-week range ($108.35–$160.27), indicating it has rebounded from the lows but remains well below the highs. This positioning suggests the stock is in a rebuilding phase, with potential for further upside if momentum sustains, but still carries the weight of the earlier decline. Short-term momentum shows a mixed picture: the 1-month change of -3.2% reflects a recent pullback, while the 3-month change of +13.2% highlights a strong recovery from the March lows. This divergence—strong 3-month gains but a weak 1-month—could signal a temporary consolidation or profit-taking after the sharp rally, rather than a reversal of the uptrend. The stock's beta of 1.255 indicates it is 25.5% more volatile than the S&P 500, amplifying both the recent recovery and the pullback. Key support lies near the 52-week low of $108.35, a level that held during the March selloff, while resistance is at the 52-week high of $160.27. A breakout above $160 would signal a resumption of the long-term uptrend, while a breakdown below $108 could indicate renewed weakness. The stock's volatility, as measured by beta, suggests that position sizing should account for larger-than-market swings.
Beta
1.25
1.25x market volatility
Max Drawdown
-29.9%
Largest decline past year
52-Week Range
$108-$160
Price range past year
Annual Return
+10.0%
Cumulative gain past year
| Period | A Return | S&P 500 |
|---|---|---|
| 1m | -3.2% | +1.4% |
| 3m | +12.2% | +10.6% |
| 6m | -10.0% | +8.4% |
| 1y | +10.0% | +20.5% |
| ytd | -4.9% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
A Fundamental Analysis
Agilent's revenue trajectory is showing steady growth, with the most recent quarter (Q1 FY2026, ended Jan 31, 2026) reporting $1.798 billion, up 6.96% year-over-year from $1.681 billion in Q1 FY2025. This marks an acceleration from the prior quarter's 5.0% growth (Q4 FY2025: $1.861B vs $1.701B), driven by strength in the Life Sciences and Applied Markets segment ($679M) and Agilent CrossLab ($758M). The Applied Markets segment contributed $361M, indicating broad-based demand. The growth trend supports the investment case for a company benefiting from secular trends in biopharma and diagnostics. Profitability remains robust, with net income of $305 million in Q1 FY2026, yielding a net margin of 17.0%, up from 12.9% in Q2 FY2025. Gross margin improved to 52.6% from 51.9% a year ago, reflecting operational efficiency and mix shifts. The company is solidly profitable, with operating margin of 19.6% in Q1, consistent with the healthcare diagnostics industry average. Agilent's balance sheet is healthy, with a debt-to-equity ratio of 0.50 and a current ratio of 1.96, indicating ample liquidity. Free cash flow (FCF) for the trailing twelve months is $993 million, translating to a FCF yield of 2.4% based on the current market cap. The company generated $268 million in operating cash flow in Q1, comfortably covering capital expenditures of $93 million, and has $1.758 billion in cash. ROE stands at 19.3%, reflecting strong returns on equity. The moderate debt levels and strong cash generation suggest Agilent can fund growth internally while returning capital to shareholders via dividends and buybacks.
Quarterly Revenue
$1.8B
2026-01
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.52%
Latest Quarter
Free Cash Flow
$993000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is A Overvalued?
Since Agilent has positive net income ($305M in Q1), the primary valuation metric is the P/E ratio. The trailing P/E is 31.9x, while the forward P/E is 19.8x, implying the market expects significant earnings growth in the coming year. The gap between trailing and forward P/E suggests that the market is pricing in a sharp earnings recovery, likely driven by margin expansion and revenue growth. Compared to the industry average (Medical - Diagnostics & Research), Agilent's trailing P/E of 31.9x is at a premium to the sector median of approximately 22x, representing a 45% premium. This premium is partially justified by Agilent's superior net margin of 18.8% versus the industry average of ~15%, and its consistent revenue growth. However, the PEG ratio of 9.4x suggests the stock is expensive relative to its growth rate, indicating that the market expects above-average growth to sustain. Historically, Agilent's trailing P/E has ranged from 15.9x (Q4 2023) to 80.6x (Q3 2023), with the current 31.9x near the lower end of its 5-year range. This suggests the stock is not overvalued by its own historical standards, but rather trading at a moderate multiple after the earnings recovery. The current P/E is below the 5-year average of ~35x, implying that the market may be cautious despite the recent beat, or that the stock has room to re-rate higher if growth continues.
PE
31.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 16x~81x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Agilent's debt-to-equity of 0.50 is moderate, but the company carries $1.758B in cash against $2.5B in debt (estimated from D/E and equity). The net margin of 17.0% is solid but has been volatile, dropping to 12.9% in Q2 FY2025 before recovering. Revenue growth of 6.96% YoY is decent but not explosive, and the PEG ratio of 9.4x suggests the market expects higher growth. Any slowdown in biopharma spending could pressure earnings. Free cash flow of $993M TTM provides a cushion, but the FCF yield of 2.4% is low, limiting the margin of safety.
Market & Competitive Risks: The stock's beta of 1.255 makes it 25.5% more volatile than the market, amplifying downside in selloffs. The trailing P/E of 31.9x is a 45% premium to the industry median, making it vulnerable to multiple compression if growth disappoints. Competitive pressures from Danaher and Thermo Fisher could erode market share. Regulatory risks in China, a key market, and potential US-Iran deal impacts on oil prices could create macro headwinds. The recent news of a US-Iran ceasefire extension provides a temporary tailwind but adds uncertainty.
Worst-Case Scenario: A combination of slowing revenue growth (below 5%), margin contraction from integration issues with Biocare, and a broad market selloff could drive the stock to its 52-week low of $108.35, representing a 17.1% decline from the current price of $130.69. In a severe recession, the stock could fall further to $100, a 23.5% loss. The historical max drawdown of -29.87% suggests a potential decline to $91.60, a 29.9% loss from current levels.
FAQ
The key risks are: (1) Valuation risk: The stock trades at a 45% premium to the industry median P/E, making it vulnerable to multiple compression if growth disappoints. (2) Growth risk: Revenue growth of 6.96% is decent but not exceptional; any deceleration below 5% could trigger a selloff. (3) Integration risk: The Biocare Medical acquisition may face execution challenges, potentially weighing on margins. (4) Macro risk: With a beta of 1.255, the stock is 25.5% more volatile than the market, and a hawkish Fed or geopolitical tensions (e.g., US-Iran, China) could pressure the stock. The most severe risk is a combination of growth deceleration and multiple compression, which could drive the stock to its 52-week low of $108.35, a 17.1% decline.
The 12-month forecast is mixed, with a base case of range-bound trading between $130 and $150 (50% probability), supported by steady mid-single-digit growth. The bull case (25% probability) targets $155-$175, driven by sustained growth acceleration and margin expansion. The bear case (25% probability) sees the stock falling to $108-$120 if growth decelerates or macro headwinds intensify. The most likely scenario is the base case, assuming Agilent achieves consensus EPS of $8.82 and revenue growth of 5-7%. The stock's current price of $130.69 is near the lower end of the base case range, offering limited upside but also limited downside from current levels.
Agilent is overvalued relative to its industry peers but fairly valued relative to its own history. The trailing P/E of 31.9x is a 45% premium to the Medical - Diagnostics & Research industry median of ~22x, indicating the market is paying up for Agilent's superior margins (net margin 18.8% vs industry ~15%) and consistent growth. However, the current P/E is below the stock's 5-year average of ~35x, suggesting it is not overvalued by its own standards. The forward P/E of 19.8x implies the market expects significant earnings growth, which is reflected in the high PEG ratio of 9.4x. Overall, the valuation is stretched but not extreme, and the stock could be considered fairly valued if growth accelerates.
Agilent is a good buy for long-term investors seeking quality exposure to life sciences, but the current valuation offers limited margin of safety. The analyst consensus is Overweight/Buy with an estimated average target of ~$175, implying 34% upside from $130.69. However, the stock trades at a 45% premium to the industry median P/E (31.9x vs 22x) and has a high PEG ratio of 9.4x, suggesting it is priced for perfection. The biggest downside risk is a growth deceleration below 5%, which could trigger multiple compression. For patient investors, a better entry point would be near $115 (52-week low), offering a 12% downside from current levels. Overall, it's a Hold at current prices, but a Buy on dips.
Agilent is better suited for long-term investment (3-5 years) due to its stable business model, recurring revenue from consumables and services, and exposure to secular biopharma trends. The stock's beta of 1.255 indicates higher volatility, making it less suitable for short-term trading without a clear catalyst. The dividend yield of 0.68% is modest, but the payout ratio of 21.6% leaves room for growth. Short-term traders may find opportunities around earnings events, but the recent 1-month decline of 3.2% and mixed technicals suggest caution. For long-term investors, the current valuation is reasonable relative to history, and the company's strong cash flow supports shareholder returns. A minimum holding period of 3 years is recommended to ride out volatility.